07.22.21
Rank: #20 (Last year: #20)
$5.57 Billion
Prior Fiscal: $5.83 Billion
Percentage Change: -4.5%
No. of Employees: 23,319
Global Headquarters: Shibuya City, Tokyo, Japan
KEY EXECUTIVES:
Shinjiro Saito, President and CEO
Hikaru Samejima, President, General Hospital Company; Division President, Hospital Systems Division
Toshihiko Osada, President, Cardiac and Vascular Company; Division President, Interventional Systems Division
Antionette Gawin, President, Blood and Cell Technologies Company; President and CEO, Terumo BCT Holding Corp.
Paul Holbrook, Division President, Vascular Graft Division; President and CEO, Vascutek Ltd.
Takeshi Kuroo, Sr. VP, Surgical Business; GM, HeartSheet Business Dept.
Robert DeRyke, Division President, Cardiovascular Division; President and CEO, Terumo Cardiovascular Systems Corp.
Tsuyoshi Tomita, Group Manager, General Hospital Products Group
Terumo business MicroVention Inc., a U.S.-based neurovascular device company, welcomed a new leader last September. New president and CEO Carsten Schroeder touts an over 25-year tenure in senior experience roles across pharma, medical devices, and in-vitro diagnostics—serving as president and CEO of Grifols, president of diagnostics at Novartis, and various VP positions at Boston Scientific.
“I am very excited to be joining the MicroVention team,” Schroeder noted in a press release. “MicroVention's reputation in their industry makes them well-positioned to becoming the global leader in the neurovascular market.”
In December, MicroVention filed a second lawsuit against Balt USA and four previous Terumo employees for trade secret misappropriation. It follows a patent lawsuit filed in July 2019 that is also ongoing.
MicroVention alleges during discovery in the first lawsuit, Balt reluctantly produced an enormous number of individual documents purloined from MicroVention. These documents were found to be part of MicroVention’s controlled docments library and knowledge management system, and MicroVention seeks $100 million in damages. At the time of writing, the lawsuit has not been resolved.
MicroVention represents a section of Terumo’s Cardiac and Vascular Company, which also manufactures interventional, cardiovascular, and vascular graft products. The business accrued 350.5 billion yen ($3.18 billion) of the company’s total $5.57 billion in total revenue in its most recent fiscal year (ended March 31, 2021). Like many others in the Top 30, that represented a loss—in Terumo’s case, of 4.5 percent. The Cardiac and Vascular Company was the firm’s most active last year.
Last January Terumo received FDA premarket approval for its FRED (Flow Re-Direction Endoluminal Device) to treat brain aneurysms. The flow diverter uses a self-expanding braided nitinol mesh to redirect blood flow and promote aneurysm occlusion. Its interwoven nitinol design facilitates smooth delivery, reliable opening, and vessel wall apposition.
Also last January, the firm launched its fluorinated urethane polyether prepolymer surgical sealant AQUABRID in the EMEA market. Specially developed for aortic procedures, it reacts with water (blood) and forms an elastic layer in three to five minutes that adheres to tissue. It has been proven safe and effective to achieve hemostasis, even when blood coagulation is inhibited during surgery.
The company’s BioPearl Microspheres gained EU approval last April. They were a new option for loco-regional embolization of target artery blood supply to liver cancer. They’re designed to preserve post TACE target artery access to open the possibility for cyclic treatment.
April also saw breakthrough device designation granted to the Thoraflex Hybrid stent for complex aortic arch repair. The single-use stent combines a gelatin-sealed woven polyester graft with a nitinol self-expanding stent graft to repair or replace damaged or diseased aortic arch vessels and descending aorta. Thoraflex Hybrid became the world’s first multi-branched “frozen elephant trunk” prosthesis when it earned a CE mark in 2012.
Terumo Aortic garnered FDA approval for the TREO abdominal aortic stent-graft system to treat abdominal aortic aneurysms last May. The endovascular aneurysm repair (EVAR) device touts dual proximal fixation and lock stent technology. A three-piece design with in situ limb adjustability allows for a wide range of aortic device configurations. According to recent clinical studies, its proximal clasping mechanism and leave-behind sheath simplify the procedure, as well. TREO launched in the U.S. in September.
Terumo purchased Netherlands-based healthcare startup Quirem Medical last July, acquiring 80.1 percent of Quirem shares and making it a wholly owned Terumo subsidiary to the tune of $45 million. Quirem produces microspheres for selective internal radiation therapy (SIRT) to treat liver tumors. QuiremSpheres contain the radioactive isotope Holmium-166, which recent trials have shown as safe and effective against unresectable liver cancer. They can be visualized and quantified in low concentrations by using single-photon emission computed tomography (SPECT) and MRI. Also brought into Terumo’s portfolio were QuiremScout, a low-dose holmium microsphere to evaluate microsphere biodistribution before therapy, and the Q-Suite dosimetry software package to plan QuiremSpheres treatments based on QuiremScout dose imaging.
A month later, following FDA emergency use authorization for COVID-19 patients with imminent or confirmed respiratory failure, Terumo and CytoSorbents Corp. began collaborating to sell the CytoSorb extracorporeal cytokine adsorber to hospitals in 10 U.S. COVID-19 hotspots. Combining Terumo’s extracorporeal membrane oxygenation (ECMO) with CytoSorb enables gas exchange and cytokine storm reduction, letting the lungs rest and potentially reduce time on mechanical lung support.
The General Hospital Company claimed 171 billion yen ($1.55 billion) in proceeds last year.
Thanks to FDA GMP certification last August, the firm began manufacturing Hulio (adalimumab-fkjp), a biosimilar to AbbVie's Humira, on contract. Hulio treats rheumatoid and psoriatic arthritis, filled in Terumo’s PLAJEX prefillable syringe whose material reduces drug adsorption risks and impurity dissolution. In June 2020, the product also received approval in Japan.
November saw a CE mark for the MEDISAFE WITH insulin pump system. The tubing-free patch pump was designed to be wearable and lightweight, consisting of two parts including detachable pump and patch. Insulin is administered subcutaneously through a cannula attached to the patch. Basal and bolus settings can be adjusted with a remote controller.
The Blood and Cell Technologies Company makes up the remainder of Terumo’s business, and pocketed 107.1 billion yen ($972 million) in its most recent fiscal year.
In April the firm obtained FDA emergency use authorization for its Spectra Optia apheresis system combined with Marker Therapeutics’ D2000 adsorption cartridge to treat adult COVID-19 patients in the ICU with imminent respiratory failure to lower pro-inflammatory cytokine levels. The devices filter the patient’s blood to reduce the number of cytokines and other small active proteins that control a cell’s immune response.
$5.57 Billion
Prior Fiscal: $5.83 Billion
Percentage Change: -4.5%
No. of Employees: 23,319
Global Headquarters: Shibuya City, Tokyo, Japan
KEY EXECUTIVES:
Shinjiro Saito, President and CEO
Hikaru Samejima, President, General Hospital Company; Division President, Hospital Systems Division
Toshihiko Osada, President, Cardiac and Vascular Company; Division President, Interventional Systems Division
Antionette Gawin, President, Blood and Cell Technologies Company; President and CEO, Terumo BCT Holding Corp.
Paul Holbrook, Division President, Vascular Graft Division; President and CEO, Vascutek Ltd.
Takeshi Kuroo, Sr. VP, Surgical Business; GM, HeartSheet Business Dept.
Robert DeRyke, Division President, Cardiovascular Division; President and CEO, Terumo Cardiovascular Systems Corp.
Tsuyoshi Tomita, Group Manager, General Hospital Products Group
Terumo business MicroVention Inc., a U.S.-based neurovascular device company, welcomed a new leader last September. New president and CEO Carsten Schroeder touts an over 25-year tenure in senior experience roles across pharma, medical devices, and in-vitro diagnostics—serving as president and CEO of Grifols, president of diagnostics at Novartis, and various VP positions at Boston Scientific.
“I am very excited to be joining the MicroVention team,” Schroeder noted in a press release. “MicroVention's reputation in their industry makes them well-positioned to becoming the global leader in the neurovascular market.”
In December, MicroVention filed a second lawsuit against Balt USA and four previous Terumo employees for trade secret misappropriation. It follows a patent lawsuit filed in July 2019 that is also ongoing.
MicroVention alleges during discovery in the first lawsuit, Balt reluctantly produced an enormous number of individual documents purloined from MicroVention. These documents were found to be part of MicroVention’s controlled docments library and knowledge management system, and MicroVention seeks $100 million in damages. At the time of writing, the lawsuit has not been resolved.
MicroVention represents a section of Terumo’s Cardiac and Vascular Company, which also manufactures interventional, cardiovascular, and vascular graft products. The business accrued 350.5 billion yen ($3.18 billion) of the company’s total $5.57 billion in total revenue in its most recent fiscal year (ended March 31, 2021). Like many others in the Top 30, that represented a loss—in Terumo’s case, of 4.5 percent. The Cardiac and Vascular Company was the firm’s most active last year.
Last January Terumo received FDA premarket approval for its FRED (Flow Re-Direction Endoluminal Device) to treat brain aneurysms. The flow diverter uses a self-expanding braided nitinol mesh to redirect blood flow and promote aneurysm occlusion. Its interwoven nitinol design facilitates smooth delivery, reliable opening, and vessel wall apposition.
Also last January, the firm launched its fluorinated urethane polyether prepolymer surgical sealant AQUABRID in the EMEA market. Specially developed for aortic procedures, it reacts with water (blood) and forms an elastic layer in three to five minutes that adheres to tissue. It has been proven safe and effective to achieve hemostasis, even when blood coagulation is inhibited during surgery.
The company’s BioPearl Microspheres gained EU approval last April. They were a new option for loco-regional embolization of target artery blood supply to liver cancer. They’re designed to preserve post TACE target artery access to open the possibility for cyclic treatment.
April also saw breakthrough device designation granted to the Thoraflex Hybrid stent for complex aortic arch repair. The single-use stent combines a gelatin-sealed woven polyester graft with a nitinol self-expanding stent graft to repair or replace damaged or diseased aortic arch vessels and descending aorta. Thoraflex Hybrid became the world’s first multi-branched “frozen elephant trunk” prosthesis when it earned a CE mark in 2012.
Terumo Aortic garnered FDA approval for the TREO abdominal aortic stent-graft system to treat abdominal aortic aneurysms last May. The endovascular aneurysm repair (EVAR) device touts dual proximal fixation and lock stent technology. A three-piece design with in situ limb adjustability allows for a wide range of aortic device configurations. According to recent clinical studies, its proximal clasping mechanism and leave-behind sheath simplify the procedure, as well. TREO launched in the U.S. in September.
Terumo purchased Netherlands-based healthcare startup Quirem Medical last July, acquiring 80.1 percent of Quirem shares and making it a wholly owned Terumo subsidiary to the tune of $45 million. Quirem produces microspheres for selective internal radiation therapy (SIRT) to treat liver tumors. QuiremSpheres contain the radioactive isotope Holmium-166, which recent trials have shown as safe and effective against unresectable liver cancer. They can be visualized and quantified in low concentrations by using single-photon emission computed tomography (SPECT) and MRI. Also brought into Terumo’s portfolio were QuiremScout, a low-dose holmium microsphere to evaluate microsphere biodistribution before therapy, and the Q-Suite dosimetry software package to plan QuiremSpheres treatments based on QuiremScout dose imaging.
A month later, following FDA emergency use authorization for COVID-19 patients with imminent or confirmed respiratory failure, Terumo and CytoSorbents Corp. began collaborating to sell the CytoSorb extracorporeal cytokine adsorber to hospitals in 10 U.S. COVID-19 hotspots. Combining Terumo’s extracorporeal membrane oxygenation (ECMO) with CytoSorb enables gas exchange and cytokine storm reduction, letting the lungs rest and potentially reduce time on mechanical lung support.
The General Hospital Company claimed 171 billion yen ($1.55 billion) in proceeds last year.
Thanks to FDA GMP certification last August, the firm began manufacturing Hulio (adalimumab-fkjp), a biosimilar to AbbVie's Humira, on contract. Hulio treats rheumatoid and psoriatic arthritis, filled in Terumo’s PLAJEX prefillable syringe whose material reduces drug adsorption risks and impurity dissolution. In June 2020, the product also received approval in Japan.
November saw a CE mark for the MEDISAFE WITH insulin pump system. The tubing-free patch pump was designed to be wearable and lightweight, consisting of two parts including detachable pump and patch. Insulin is administered subcutaneously through a cannula attached to the patch. Basal and bolus settings can be adjusted with a remote controller.
The Blood and Cell Technologies Company makes up the remainder of Terumo’s business, and pocketed 107.1 billion yen ($972 million) in its most recent fiscal year.
In April the firm obtained FDA emergency use authorization for its Spectra Optia apheresis system combined with Marker Therapeutics’ D2000 adsorption cartridge to treat adult COVID-19 patients in the ICU with imminent respiratory failure to lower pro-inflammatory cytokine levels. The devices filter the patient’s blood to reduce the number of cytokines and other small active proteins that control a cell’s immune response.